bluebird bio

BLUENASDAQDelisted

Lentiviral gene therapy platform

Drafted with AI assistance from public sources and not individually reviewed by an editor; last updated 2026-04-09. Published by ClinicalInvestor. Educational analysis only. Read the editorial policy and disclosures.

text updated 2026-04-09, 222 days ago · archived: kept for reference, not maintained · where each field comes from

Pipeline at the time of the last update

DrugIndicationPhaseExpected data
Lyfgeniasickle cell diseaseApprovedNot disclosed▼
Zynteglotransfusion-dependent beta thalassemiaApprovedNot disclosed▼
Skysonacerebral adrenoleukodystrophyApprovedNot disclosed▼


Comparable companies

Sarepta TherapeuticsCRISPR TherapeuticsRocket Pharmaceuticals
Disclaimer: This page is for informational and educational purposes only and does not constitute financial advice or a recommendation to buy or sell securities. Clinical trial analysis reflects publicly available data and AI-generated interpretations. Biotech investing carries significant risk including potential total loss of investment. Always verify critical claims through primary sources and consult a qualified financial advisor. Some links on this page are affiliate links. Review our editorial policy and disclosures.